None of these mutations were known oncogenic/targetable mutations, except for an irregular SPTBN1~ALK fusion gene that retained the complete kinase domain of ALK. The presence of ALK fusion suggested that CRC might benefit from ALK-targeted therapies. Here, ALK is linked to colorectal carcinoma.